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Background: MOH can be diagnosed in subjects with headache occurring 15
days/month in association with a regular medication overuse, but its existence is
not universally accepted. ICHD-3 redefined criteria for MOH, removing the criterion
associating drug suspension with headache course. The aim of our study was to
compare the rate of patients diagnosed with medication overuse headache (MOH)
according to ICHD-2 and ICHD-3 criteria, to verify the degree of concordance. The
secondary aim was to verify if drug withdrawal was really associated with pain relief.
Methods: In this cross-sectional study, we retrospectively analyzed a sample of 400
patients followed for primary chronic headache at the Headache Center of Bambino
Gesù Children’s Hospital. We then selected those presenting with a history of medication
overuse, and we applied both ICHD-2 and ICHD-3 criteria to verify in which patients the
criteria would identify a clinical diagnosis of MOH.
Results: We identified 42 subjects (10.5%) with MOH; 23 of them (55%) presented a
relief of headache withdrawing drug overuse. Regarding the applicability of the ICHD-2
criteria, 43% of patients (18/42) fulfilled all criteria, while all ICHD-3 diagnostic criteria
were satisfied in 76% of patients (32/42). Eighteen patients (43%) satisfied both ICHD-2
and ICHD-3 criteria, while 10 patients (24%) did not satisfy either diagnostic criterion.
Conclusions: Our study suggests that in children and adolescents, withdrawing
medication overuse is not always associated with a clinical benefit. Therefore, though
allowing a MOH diagnosis in a higher rate of patients as compared to ICHD-2, the
application of ICHD-3 criteria does not guarantee a true a causal relationship between
medication overuse and headache worsening.
Keywords: chronic migraine, medication overuse headache, children, ICHD-3 criteria, secondary headache,
treatment
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INTRODUCTION
Medication overuse headache (MOH) is a headache occurring on
15 or more days/month in a patient with a preexisting primary
headache and developing as a consequence of regular overuse of
acute or symptomatic headache medication (on 10 or more or
15 or more days/month, depending on the medication) for more
than 3 months (1). MOH is listed as a secondary headache, in
the section focused on “Headache attributed to a substance or
its withdrawal.”
Although pathophysiologic mechanisms of MOH are still
largely unclear, a genetic predisposition likely plays an important
role (2, 3). Another potentially significant pathogenetic factor
taken into consideration is the interaction between drugs used
and neurotransmitters (4) and/or hormonal systems (5). Other
factors investigated over time include the presence of abnormal
neuronal excitability (6) and changes in gray matter volumes (7)
and cerebral metabolism (8–10).
The overall prevalence of MOH in the general population is
0.5–2.6%, although it varies between different studies, probably
as a consequence of different diagnostic criteria published over
time and different methods used to collect epidemiological data
(10, 11). Very few epidemiological studies are available in the
pediatric population. Data from Norway and Taiwan report
prevalence rate of 0.2 and 0.3%, respectively (12, 13). Data from
pediatric populations with chronic primary headache disorders
report a medication overuse in 10–60% of cases (14). Both in
adults and in children,MOH appears to bemore common among
females than among males (15, 16). Hopefully, a planned study
will clarify some aspect of pediatric MOH (17). This trial plans
to evaluate whether the frequency of acute medication overuse is
associated with headache frequency in children and adolescents,
and the outcomes will be frequency of headache, change in
headache frequency in relation to use of acute medications, and
headache-related disability (17).
MOH clinical features are usually the same of preexisting
primary headache disorder (10). In pediatric patients, it is
more commonly associated with chronic migraine (CM) (18).
Non-steroid anti-inflammatory drugs (NSAIDs) are the class
of drugs more often overused, followed by paracetamol and
triptans (15). Historically, the treatment of MOH includes two
main strategies: a detoxification program with discontinuation
of drugs overused and initiation of pharmacological and non-
pharmacological preventive therapy (10).
In the last two decades, diagnostic criteria for MOH were
gradually changed. Initially, MOH could be diagnosed only if
the headache resolved or reverted to the previous pattern within
2 months after withdrawal of the overused medication (19).
In the revision of diagnostic criteria published in 2006 (20),
the Headache Classification Committee proposed to remove the
criterion concerning the effect of drug suspension on headache
course, and this modification was kept in the last published
version of ICHD-3 (Table 1) (1).
Therefore, MOH can be presently diagnosed in a subject with
a history of a preexisting primary headache, presenting with
headache occurring 15 days per month in association with a
regular medication use exceeding specific thresholds.
TABLE 1 | Diagnostic criteria for MOH by ICHD-2 (2004) [(35) and by ICHD-3 (1)].
ICHD-2 ICHD-3
A. Headache present on ≥15
days/month fulfilling criteria C
and D
B.Regular overuse for ≥3
months of one or more drugs
that can be taken for acute
and/or symptomatic treatment of
headache
C. Headache has developed or
markedly worsened during
medication overuse
D. Headache resolves or reverts
to its previous pattern within 2
months after discontinuation of
overused medication
A. Headache occurring on ≥15
days/month in a patient with a
preexisting headache disorder
B. Regular overuse for >3
months of one or more drugs
that can be taken for acute
and/or symptomatic treatment of
headache
C. Not better accounted for by
another ICHD-3 diagnosis
A direct consequence of new criteria could be an increase in
definite diagnosis, since MOH can now be diagnosed even in
the absence of improvement after drug withdrawal. However,
diagnostic criteria and even the existence of this specific
nosographic entity are not universally accepted. For instance,
some authors wondered whether medication overuse is the real
cause of headache in all subjects fulfilling diagnostic criteria
for MOH (14, 19, 21). Indeed, in some individuals medication
overuse can increase headache frequency, and discontinuing
the medications can have a benefit, but this is not the case in
all individuals overusing medications. In some case, increasing
headache frequency represents a worsening of the primary
headache disorder, and increased use of acute medications is its
consequence (14).
The aim of our study was to compare the rate of patients
diagnosed with MOH according to the old ICHD-2 and new
ICHD-3 criteria, in order to verify the degree of concordance
and understand if the new classification really led to different
diagnostic rates. The secondary aim was to verify if drug
withdrawal is really associated with pain relief and therefore to
investigate in a large sample of pediatric patients whether MOH
is a true entity.
MATERIALS AND METHODS
In this cross-sectional study, we retrospectively analyzed a sample
of patients followed at the Headache Center of the Neuroscience
Department of Bambino Gesù Pediatric Hospital in Rome. We
included all patients with chronic headache, diagnosed according
to the ICHD-3 criteria (1), and followed up at our Headache
Center in the period 2010–2018, whose parents gave their
informed consent to be contacted for retrospective studies. The
sample was partially published in Papetti et al. (18). In particular,
210 out of 377 patients included in the Papetti et al.’s sample
(collected between 2010 and 2016) were considered for the
present study while the remaining 190 patients were totally
original. Moreover, only 20 out 42 of the MOH patients were
issued from the Papetti et al. population, while the remaining
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FIGURE 1 | Flowchart showing patients’ disposition.
22 patients are totally original. As compared to Papetti et al., the
present study investigated different points: (1) the comparison of
the applicability of the ICHD-2 and ICHD-3 criteria of pediatric
MOH patients and (2) the clinical outcome after medication
withdrawal in MOH children and adolescents.
Among these patients, we selected those presenting with a
personal history of medication overuse, defined as regular use
of abortive therapy: at least 10 days per month for ergotamine,
triptans, opioids, or combination-analgesic medication and 15 or
more days per month for non-opioid analgesics (paracetamol,
non-steroidal anti-inflammatory drug, or acetylsalicylic acid).
Overuse should have been carried on for at least 3 months. In all
patients, the clinical diagnosis of MOH was tested according to
either ICHD-2 or ICHD-3 version criteria, in order to verify the
degree of concordance. The diagnoses were made independently
by two experienced neurologists, blinded to each other’s rating
(MV, LP). All these data were initially extrapolated by clinical
charts and then confirmed and deeply investigated during follow-
up visits and/or telephonic interviews.
Clinical data collected for each patient were the preexisting
primary headache type, the clinical characteristics of headache
and other symptoms associated, and the treatment used, both
symptomatic and prophylactic.
The usual therapeutic strategy was an intensive verbal advice
to discontinue the medication overuse, with the suggestion of
a different symptomatic treatment than the overused one. In
almost all cases, a preventive medication was also proposed, at
this same time. Medication withdrawal was considered successful
if criteria for overuse were no more satisfied, and it was
conducted over a 2-months period. The outcome of medication
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withdrawal was assessed after two additional months of follow-
up, and it was considered effective if chronic headache reverted
to episodic.
Ethical Board approval for retrospective study was obtained.
Statistical Analysis
Statistical analysis was conducted by SPSS version 22.0. To test
the hypothesis of a possible association between response to
medication withdrawal and sex, type of overusedmedication, and
preventive treatment, we used the χ2 test. A p-value of≤0.05 was
considered significant.
Furthermore, a multiple-regression logistic analysis has been
used to evaluate whether age, age at first attack (0–6, 7–
10, 11–14, 15–18 years), or type of preventive treatment
(topiramate, 5-hydroxytryptophan, flunarizine, amitriptyline)
influenced response to withdrawing overused medication.
Response to medication withdrawal was selected as a dependent
variable, and then all the other variables have been tested as
independent variables in a block entry to evaluate the t value, the
significance, the standard error, and the upper and lower limit in
a confidence interval of 95%.
RESULTS
We collected and analyzed clinical data from a sample of 400
patients (134M, 266 F) with primary chronic headache. There
were no missing data in our sample. Seventy-five percent of
patients presented with CM, 13% with chronic tension-type
headache, and 12% with new daily persistent headache (NDPH)
(Figure 1). In 11% of patients (10 patients with NDPH and 37
with CM), migraine with aura (Mwa) was diagnosed.
In this sample, we identified 42 subjects (10.5%, Table 2) with
symptomatic medication overuse defined as above (at least 10
days per month for ergotamine, triptans, and opioids and 15 or
more days per month for non-opioid analgesics). The sample
was mainly composed of females (11M, 26%−31 F, 74%), with
a mean age of 13 years at their first medical examination (range:
8–17 years). All patients (100%) presented CM, and 9% (4/42)
presented also Mwa. The age at onset of headache was ≤6 years
in 9% of patients (4/42), 7–10 years in 29% (12/42), 11–14 years
in 48% (20/42), and 15–18 in 14% (6/42). The mean duration of
medication overuse was 4.1 months (range 3–6 months).
Photophobia and phonophobia were both present in 81%
of patients (34/42), nausea and vomiting in 71% (30/42),
and dizziness in 42% (18/42). All patients used NSAIDs as
symptomatic treatment; 21% of the sample (9/42) used triptans
as further option after a poor response to NSAIDs. Moreover,
prophylactic treatment was prescribed in 93% (39/42) of patients,
including drug-naïve patients and those who were assuming
an ineffective prophylactic therapy. Amitriptyline was the most
used drug (79%, 33/42); topiramate was used in 38% (16/42),
flunarizine in 28% (12/42), and tryptophan in 15% (6/42).
More than one type of prophylactic drug was used in 28% of
the sample (12/42; these patients were already assuming one
prophylactic drug at the time of our first visit). After withdrawing
symptomatic drug overuse, a clear benefit was evident only in
23/42 subjects (55%).
TABLE 2 | Demographic features of patients with chronic migraine and
medication overuse.
N %
Patients 42 100
Mean age: 13 years (range 8–17 years) – –
Sex
•Males 11 26
•Females 31 74
Diagnosis
•Chronic migraine 42 100
•Migraine with aura 4 9
Age at onset
•<6 years 4 9
•7–10 years 12 29
•11–14 years 20 48
•15–18 years 6 14
Symptoms associated
•Photophobia 34 81
•Phonophobia 34 81
•Nausea and vomit 30 71
•Dizziness 18 42
Symptomatic treatment 42 100
•NSAIDs 42 100
•Triptans 9 21
Prophylactic treatment 39 93
•Amitriptyline 31 79
•Topiramate 15 38
•Flunarizine 11 28
•Tryptophan 6 15
Regarding the applicability of the ICHD-2 criteria, 43% of
patients (18/42) fulfilled the diagnosis ofMOHwhile 57% (24/42)
did not fulfill all the diagnostic criteria (Figure 2). In detail, 21/42
patients (50%) fulfilled criterion A; 35/42 (83%) criterion B, 37/42
(88%) criterion C, and 23/42 (55%) criterion D (Figure 3A).
On the other hand, all ICHD-3 diagnostic criteria were
fulfilled in 76% of patients (32/42, Figure 1). Specifically, ICHD-
3 criterion A was fulfilled by 40/42 patients (95%), criterion B by
35/42 (83%), and criterion C by 40/42 (95%) (Figure 3B).
Eighteen patients (43%) satisfied both ICHD-2 and ICHD-
3 criteria, while 10 patients (24%) did not satisfy either
diagnostic criterion.
None of the analyzed variables (age at evaluation, age
at first attack, or type of preventive treatment) showed a
statistical significance at the multivariate analysis (Table 3). The
improvement after drug overuse withdrawal was observed in
20/31 (65%) of the females of our sample, compared with 3/8
(38%) ofmales (p= 0.03). However, we have to underline that our
sample was mainly composed of females. The type of overused
drug was not associated with response to withdrawal (p= 0.93).
DISCUSSION
Our retrospective study on a large sample of pediatric patients
revealed that the application of ICHD-3 criteria allows a MOH
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FIGURE 2 | Different diagnostic rate of Medication Overuse Headache according to ICHD-2 criteria (A) vs. ICHD-3 criteria (B).
diagnosis in a higher rate of patients (76 vs. 43%), thus proving
more sensitive than ICHD-2 criteria. The main difference
between the two versions is that ICHD-3 criteria do not require
remission or improvement of headache after the regular drugs
overuse is stopped. However, ICHD-3 version, removing the
relationship between pain and drug overuse, seems to consider
the MOH as a fully established diagnosis, while it is still a matter
of debate. In ICHD-2, only 50% of patients satisfied criterion A,
sincemany patients did not satisfy criteria C andD. As for ICHD-
3, the two patients not satisfying this criterion were adolescents
who received the first diagnosis of migraine after initiating the
abuse. In both versions of ICHD, only 83% of patients satisfied
criterion B, since the remaining 17% of patients presented an
overuse of medication for <3 months. Finally, two patients did
not satisfy ICHD-3 criterion C since after a careful examination
of data it was doubtful if they could be classified as “Headache
attributed to non-vascular intracranial disorders.”
A second crucial finding of our study is that in our sample
symptomatic drug withdrawal was not always sufficient to revert
chronic to episodic migraine, thus strengthening the concept
that, in turn, medication overuse was probably not sufficient
to make our patients’ migraine become chronic. Specifically,
in our sample, medication withdrawal did not cause any
reduction in headache frequency in almost half of patients (45%).
Furthermore, 22/23 patients (95%) showing an improvement of
symptoms after drug withdrawal (meaning a return to episodic
headache) were assuming a preventive therapy at the same time.
Therefore, it is very difficult to judge if the positive effect on
headache frequency was caused by one or the other therapeutic
approach used.
The few studies published on MOH in pediatric age show
a response rate to drug withdrawal (defined as a reduction
more than 50% of headache frequency) between 40 and 77%
(2, 22–24). On the other hand, a lack of improvement after drug
withdrawal is reported in 4–41% of patients (Table 3). A genetic
study on a pediatric population with CM andmedication overuse
identified statistically significant gene expression differences
between responders and non-responders to withdrawal, thus
suggesting a possible biomarker to distinguish true MOH
patients from chronicmigraineurs in whom overusedmedication
does not have a pathophysiological role (2).
Considering also MOH studies in adults, we found limited
evidence supporting a clear benefit of discontinuation of
symptomatic medications without concomitant introduction of
a preventive therapy (25). In particular, clear clinical benefits
after only withdrawing overused medication have been described
in less than one third of reported patients (26–28). Another
important bias of the available studies is represented by
patients who pretend to have withdrawn symptomatic treatment,
while keeping overusing drugs. Furthermore, randomized
controlled clinical trial investigating topiramate (29, 30) and
onabotulinumtoxinA (31, 32) for treatment of CM showed
that immediate initiation of preventive treatment without early
suspension of the overused medication is effective in patients
with CM and medication overuse (33). Most of these studies
also lacked an adequate control group, thus making it impossible
to differentiate patients presenting a benefit due to the typical
cyclic pattern of headache, and those really responding to
overuse cessation. Some authors hypothesized that medication
overuse can be seen as an epiphenomenon of a chronic headache
presenting with periods of higher frequency and severity (19),
thus suggesting that a combined strategy of preventive therapy
and overuse cessation could be more appropriate. Indeed, a
recent review of the available literature data concluded that
the combined approach of discontinuation of overused acute
medications and a concurrent preventive intervention should be
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FIGURE 3 | Applicability of ICHD-2 (A) and ICHD-3 (B) diagnostic criteria for MOH.
TABLE 3 | Results of multiple-regression logistic analysis: beta coefficients and significance, with lower and upper limits at 95% confidence interval.
β coefficient ± standard error Significance Confidence interval (95%)
Age 0.001 ± 0.004 0.882 −0.007; 0.009
Age at migraine onset 0–6 years −0.483 ± 0.375 0.207 −1.246; 0.280
Age at migraine onset 7–10 years −0.246 ± 0.232 0.295 −0.718; 0.225
Age at migraine onset 11–14 years −0.022 ± 0.155 0.213 −0.117; 0.508
Age at migraine onset 15–18 years −0.005 ± 0.262 0.934 −0.554; 0.511
Topiramate −0.005 ± 0.207 0.981 −0.427; 0.416
Flunarizine 0.065 ± 0.236 0.785 −0.415; 0.545
TriptOH −0.339 ± 0.273 0.223 −0.895; 0.217
Amitriptyline 0.179 ± 0.201 0.379 −0.229; 0.587
the standard of care (25), as already recommended by EFNS
(European Federation of Neurological Societies) guidelines for
MOH (34).
Limitations of the Study
Our study certainly presents some limitations. First of all,
the retrospective nature of the study is a limitation in itself.
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Furthermore, our population might not be representative of the
general population, as patients have been recruited in a tertiary
headache center. However, it is also important to underline that
patients suffering from chronic headache andmedication overuse
usually refer to tertiary centers, and therefore, our sample might
be overlapping to general pediatric MOH samples. Furthermore,
some patients could present with comorbidities, such as obesity,
anxiety, and depression, which could influence the outcome
but that have not been taken into consideration in the present
analysis. Lastly, the information of drug use is based on patients’
diary, and especially in case of adolescents, these data might not
always be completely reliable.
CONCLUSIONS
In conclusion, our data on a large pediatric population of
subjects with chronic headache and medication overuse show
that withdrawing medication overuse is not always associated
with a clinical benefit. This means that a causal relationship
between medication overuse and headache worsening is not
always demonstrable, thus suggesting that the concept of MOH
might be not universally applicable. Although ICHD-3 criteria
for MOH appear to be more sensitive than ICHD-2, allowing a
definite diagnosis in a higher number of patients, they do not
contribute to make this issue less puzzling, since the new ICHD
version considers MOH as a definite nosographic entity, which
is not supported by the present literature. In other words, if the
effect of drug suspension on headache course is not verified,
a sure relationship between medication overuse and headache
chronification cannot be demonstrated in all patients. A proposal
for a new systematic review on pediatric MOH has been recently
published (17) and will hopefully contribute to clarify this issue.
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